Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. De plus, nous expédions PCSK9 Kits (77) et PCSK9 Protéines (64) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 160 products:
Human Polyclonal PCSK9 Primary Antibody pour ChIP, IHC (p) - ABIN268772
Cohen, Pertsemlidis, Kotowski, Graham, Garcia, Hobbs: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. dans Nature genetics 2005
Show all 10 Pubmed References
Human Polyclonal PCSK9 Primary Antibody pour ELISA, WB - ABIN4347756
Kwon, Lagace, McNutt, Horton, Deisenhofer: Molecular basis for LDL receptor recognition by PCSK9. dans Proceedings of the National Academy of Sciences of the United States of America 2008
Human Polyclonal PCSK9 Primary Antibody pour IF (p), IHC (p) - ABIN761831
Jia, Song, Yang, Ma, Li, Lu, Cao, Zhang, Zhu, Wang, Leng, Cao, Du, Xu: Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats. dans Molecular medicine reports 2016
Human Polyclonal PCSK9 Primary Antibody pour ELISA, IP - ABIN4347755
Lalanne, Lambert, Amar, Chétiveaux, Zaïr, Jarnoux, Ouguerram, Friburg, Seidah, Brewer, Krempf, Costet: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. dans Journal of lipid research 2005
LY3015014 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that binds to the catalytic domain of PCSK9.
Increased PCSK9 levels are associated with higher platelet reactivity and predictive of ischemic events in acute coronary syndrome.
Identify LDLR (Montrer LDLR Anticorps), APOB (Montrer APOB Anticorps) and PCSK9 novel mutations causing familial hypercholesterolemia in the central south region of China.
Both circulating PCSK9 and SORT1 (Montrer SORT1 Anticorps) levels are elevated in coronary artery disease patients.
Rare variants of APOB (Montrer APOB Anticorps) or PCSK9 were identified in nine of the 22 study patients with extremely low LDL-C levels
PCSK9 plays a direct role on Abca1 (Montrer ABCA1 Anticorps)-mediated cholesterol efflux through a downregulation of Abca1 (Montrer ABCA1 Anticorps) gene and Abca1 (Montrer ABCA1 Anticorps) protein expression. This extrahepatic effect may influence relevant steps in the pathogenesis of atherosclerosis, such as foam cell formation.
kidney function per se does not impact significantly PCSK9 metabolism
Sirolimus therapy in heart transplant patients is associated with elevation in PCSK9 levels which is not associated with sirolimus-induced hypercholesterolemia.
PCSK9 inhibits lipoprotein(a) clearance through the LDLR (Montrer LDLR Anticorps).
PCSK9 variants reduced fasting LDL-C as well as fasting triglycerides.
Use Crispr-Cas (Montrer CTNND1 Anticorps) system to introduce nonsense variants into PCSK9 to lower blood cholesterol levels.
Studied the combination model of a single AAV-PCSK9 injection, high-fat diet, and partial carotid ligation which induces robust atherosclerosis in the flow-disturbed carotid artery within 3 weeks in C57 mice, and results suggest this is a quick and convenient model to study atherosclerosis and mechanisms using any knockout or transgenic mice without having to generate double knockouts.
These observations suggest positive feedback interplay between SMC (Montrer DYM Anticorps)-derived PCSK9 and mtDNA damage in the proinflammatory milieu involving mtROS. This interaction results in cellular injury, characterized by apoptosis-a hallmark of atherosclerosis.
AdipoR activation by agonists regulated PCSK9 expression and inhibits atherosclerosis in apoE (Montrer APOE Anticorps)(-/-) mice.
Adeno (Montrer ADORA2A Anticorps)-associated virus mediated infection with a mouse PCSK9 gain-of-function mutation is a rapid, easy, and efficient approach for inducing hypercholesterolemia and promoting abdominal aortic aneurysms in C57BL/6 mice infused with angiotensin II.
conditions that cause ER stress regardless of their ability to dysregulate ER Ca(2 (Montrer CA2 Anticorps)+) inhibit PCSK9 secretion, thereby reducing PCSK9-mediated LDLR (Montrer LDLR Anticorps) degradation and promoting LDLR (Montrer LDLR Anticorps)-dependent hepatic cholesterol uptake.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor (Montrer LDLR Anticorps) Degradation.
PCSK9 increases hepatic lipid and lipoprotein production via apoE (Montrer APOE Anticorps)- and LDLR (Montrer LDLR Anticorps)-dependent mechanisms
Podocyte damage triggers marked inductions in plasma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.
This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
proprotein convertase subtilisin/kexin type 9
, convertase subtilisin/kexin type 9 preproprotein
, neural apoptosis regulated convertase 1
, subtilisin/kexin-like protease PC9
, convertase subtilisin
, neural apoptosis-regulated convertase 1
, proprotein convertase 9
, proprotein convertase PC9
, proprotein convertase subtilisin/kexin type 9 preproprotein
, Proprotein convertase 9
, Subtilisin/kexin-like protease PC9